TrialActa neurologica Scandinavica2014

OnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received all five treatment cycles in the PREEMPT clinical program.

S K Aurora et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.